OP Asset Management Ltd Acquires Shares of 23,477 Alnylam Pharmaceuticals, Inc. $ALNY

OP Asset Management Ltd bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm bought 23,477 shares of the biopharmaceutical company’s stock, valued at approximately $7,768,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Assenagon Asset Management S.A. grew its position in shares of Alnylam Pharmaceuticals by 403.7% in the first quarter. Assenagon Asset Management S.A. now owns 128,896 shares of the biopharmaceutical company’s stock valued at $42,648,000 after purchasing an additional 103,306 shares in the last quarter. Faithward Advisors LLC lifted its position in Alnylam Pharmaceuticals by 5.0% during the first quarter. Faithward Advisors LLC now owns 3,961 shares of the biopharmaceutical company’s stock worth $1,311,000 after buying an additional 187 shares in the last quarter. Founders Financial Securities LLC acquired a new position in Alnylam Pharmaceuticals during the first quarter worth $437,000. Rockefeller Capital Management L.P. boosted its stake in Alnylam Pharmaceuticals by 85.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 8,124 shares of the biopharmaceutical company’s stock worth $3,231,000 after buying an additional 3,744 shares during the last quarter. Finally, Hsbc Holdings PLC grew its holdings in Alnylam Pharmaceuticals by 22.6% in the 4th quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after buying an additional 16,503 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $293.17 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $273.11 and a 52 week high of $495.55. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $39.14 billion, a P/E ratio of 80.10 and a beta of 0.29. The stock’s fifty day moving average is $297.10 and its two-hundred day moving average is $332.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The company’s quarterly revenue was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.44) EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on ALNY shares. Citigroup initiated coverage on Alnylam Pharmaceuticals in a research note on Tuesday, May 19th. They issued a “buy” rating and a $380.00 target price for the company. Chardan Capital reissued a “buy” rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a report on Monday, April 13th. Jefferies Financial Group restated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Finally, Wells Fargo & Company lifted their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research note on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $463.13.

Insider Activity

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the completion of the transaction, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 7,740 shares of company stock worth $2,420,214. 0.86% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.